Prevention of cardiovascular disease in current and former employees of the Ford motor company, Germany

ISRCTN ISRCTN23536103
DOI https://doi.org/10.1186/ISRCTN23536103
Secondary identifying numbers N/A
Submission date
26/05/2011
Registration date
28/07/2011
Last edited
14/03/2023
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Cardiovascular diseases (CVD), including heart disease, heart attack and stroke, are a major cause of suffering and disability in many patients. Therefore, there is an urgent need for treatment strategies to prevent CVD, especially in healthy individuals at high risk for CVD. Decades of research have shown that CVD results from multiple risk factors, including smoking, high blood cholesterol, high blood pressure, obesity, chronic stress and depression. Treatment strategies for single risk factors are available, but, until now, only very few studies have targeted all of the aforementioned risk factors at the same time in a larger sample of healthy individuals at high risk for CVD. This study aims to fill this gap. The aim of this study is to find out whether the PreFord intervention reduces the risk of CVD.

Who can participate?
Adults with no evidence of existing CVD, but at high risk for CVD in the future

What does the study involve?
Participants are randomly allocated to either the PreFord intervention or routine care by their GPs. The PreFord intervention consists of 75 hours (total), divided into 30 sessions (2.5 hours each), two times a week, over a period of 15 weeks. It includes health education (e.g., the heart and vessels, healthy food, heart medication, etc), exercise, a smoking cessation programme if necessary, and LifeSkills, an approach to enhance stress resilience and social relationships at work and leisure time. The intervention is accompanied by a guideline-based drug treatment for high blood cholesterol and high blood pressure, if necessary. Well being, health behaviour and CVD risk factors are assessed before and after the intervention, and annually for 5 years. The intervention and each follow-up assessment are free of charge, and participants are free to join or leave the study whenever they wish.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
German Sports University Cologne

When is the study starting and how long is it expected to run for?
August 2004 to July 2013

Who is funding the study?
Bayer Vital (Germany), Pronova BKK (Germany) and AstraZeneca (Germany)

Who is the main contact?
Prof. Hans-Georg Predel
predel@dshs-koeln.de

Contact information

Prof Hans-Georg Predel
Scientific

German Sports University Cologne
Cologne (Koeln)
50931
Germany

Email predel@dshs-koeln.de

Study information

Study designTwo-armed randomized controlled clinical trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typePrevention
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleMultimodal intervention for prímary prevention of cardiovascular disease in current and former employees of the Ford motor company, Germany - the PreFord trial
Study acronymPreFord
Study objectivesA multimodal intervention for primary prevention of cardiovascular disease (CVD) will reduce multiple biological and psychosocial cardiac risk factors and cardiac events.

Re-evaluation of cardiovascular risk and cardiac events annually up to 5 years.
Ethics approval(s)1. North Rhine Medical Association (Aerztekammer North Rhine) Ethics Committee, 20/12/2004, ref: 2004079
2. Faculty of Medicine Ethics Committee, University of Cologne, 02/02/2004, ref: 03-217
Health condition(s) or problem(s) studiedPrevention of cardiovascular disease
InterventionMultimodal intervention for outpatients, two sessions a week in the afternoon for three months (75 hours total):
1. Health education
2. Exercise therapy
3. Smoking cessation programme
4. Stress management (LifeSkills)
Intervention typeOther
Primary outcome measureEuropean Society of Cardiology risk score
Secondary outcome measures1. Health behaviour (physical fitness, smoking, BMI)
2. CVD risk factors, e.g. low-density-lipoprotein cholesterol (LDL-C), total cholesterol, trigycerides, blood pressure, diabetes mellitus, depression and anxiety (HADS), Type-D pattern (DS-14)
Overall study start date01/08/2004
Completion date31/07/2013

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants447
Total final enrolment447
Key inclusion criteria1. Adult men and women with no evidence for CVD and elevated risk according to the (European Society of Cardiology) ESC risk score > 5%
2. Informed consent
Key exclusion criteriaSevere somatic or psychiatric morbidity, e.g. malignancies, psychosis, drug addiction
Date of first enrolment01/08/2004
Date of final enrolment31/07/2013

Locations

Countries of recruitment

  • Germany

Study participating centre

German Sports University Cologne
Cologne (Koeln)
50931
Germany

Sponsor information

German Sports University (Germany)
University/education

c/o Prof Dr HG Predel
Cologne
50931
Germany

Email predel@dshs-koeln.de
Website https://www.dshs-koeln.de/wps/portal
ROR logo "ROR" https://ror.org/0189raq88

Funders

Funder type

Industry

Bayer Vital (Germany)

No information available

Pronova BKK (Germany)

No information available

AstraZeneca (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/02/2004 Yes No
Results article results 01/02/2012 Yes No
Results article results 01/09/2017 Yes No
Other publications Secondary analysis 23/02/2023 14/03/2023 Yes No

Editorial Notes

14/03/2023: Publication reference and total final enrolment added.
12/07/2017: Publication reference added.
19/02/2016: Plain English summary added.